DCF — SENTARA ALBEMARLE REGL MED CTR LLC
Enterprise Value: $-51.3M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-51.3M
Enterprise Value
$-20.0M
PV of Cash Flows
$-31.3M
PV of Terminal Value
$-50.3M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $144.5M | $-1.1M | -1.0% | $-7.2M | $-6.6M |
| Year 2 | $148.8M | $0.3M | 0.0% | $-6.0M | $-4.9M |
| Year 3 | $153.3M | $1.9M | 1.0% | $-4.6M | $-3.5M |
| Year 4 | $157.9M | $2.7M | 2.0% | $-4.0M | $-2.7M |
| Year 5 | $162.7M | $3.2M | 2.0% | $-3.7M | $-2.3M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-51.3M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$140.3M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.012814343971953203
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5